je.st
news
Home
› Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
Catabasis And ActiGraph Collaborate On An Observational Trial To Explore The Benefits Of Daily Physiological Activity Monitoring In Patients With Duchenne Muscular Dystrophy
2015-12-02 02:15:49| drugdiscoveryonline Home Page
Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, recently announced a collaboration to explore the potential utility of daily physiological activity monitoring in boys affected by Duchenne muscular dystrophy (DMD) with ActiGraph, a leading provider of objective physical activity and sleep/wake measurement solutions for the global scientific community
Tags: with
daily
activity
trial
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||